MAD2L2

Across TCGA pan-cancer cohorts, MAD2L2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MAD2L2 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MAD2L2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MAD2L2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where MAD2L2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.922	0.409	.024	3	view →
HNSC	DFS	Median	II,III,IV	0.833	0.698	.040	2	view →
CCRCC	OS	Median	All	0.687	1.000	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MAD2L2–LUAD (DFS)

Open the LUAD breakdown →